components. The authors found that nuclear envelope components that incorporated efficiently into micronuclei were those com ponents known 8 to localize to the core regions of reassembling nuclei. The nuclearenvelope components that were inefficiently incorpo rated or absent from micronuclei were those that are found on the noncore regions of reas sembling nuclei.
Liu and colleagues investigated whether the failure of lagging chromosomes to recruit noncore nuclearenvelope components depends on the presence of the spindle. The authors treated cells undergoing cell division with drugs that dismantled the spindle. This treatment enabled both core and noncore nuclearenvelope components to assemble on lagging chromosomes that were form ing micronuclei. The authors also conducted experiments in which they manipulated cells to displace some chromosomes away from the spindle to peripheral regions of a dividing cell. These displaced chromosomes formed micronuclei that had both core and noncore nuclearenvelope components. Such micronu clei did not rupture, revealing that noncore components are needed to prevent micro nuclear fragility. The authors' results are con sistent with a model in which the micronuclear assembly of nuclearenvelope material is per turbed in regions of the cell that have a high density of microtubules.
Cell division is a highly regulated process, and there are mechanisms to ensure its quality control. This raises the question of whether any such checkpoints exist in human cells to deal with lagging chromosomes.
In the fruit fly Drosophila melanogaster, there is a gradient of activity of the kinase enzyme Aurora B that is highest near the spindle in the centre of a dividing cell 9 . This enzymatic activ ity inhibits nuclearenvelope reassembly on lag ging chromosomes that are within the region of high Aurora B activity. This mechanism for inhibiting nuclearenvelope reassembly might facilitate the reintegration of a lagging chro mosome with the rest of the chromosomes that will form the new nucleus 9 . Indeed, when Aurora B is mislocalized away from the spindle in Drosophila cells 9 , nuclearenvelope material, such as the noncore, nuclearporecomplex protein Nup107, binds to lagging chromo somes with the same kinetics as to the main chromosome group.
However, when Liu et al. caused similar perturbations of Aurora B in human cells, this did not restore the recruitment of a non core, nuclearporecomplex protein (in this case, Nup133) to lagging chromosomes. The contrasting outcomes might reflect species specific differences in sensitivity to Aurora B perturbations. Liu and colleagues found that core nuclearenvelope components accumu lated on lagging chromosomes with normal kinetics and that drugmediated inhibition of Aurora B at a late stage of cell division just before nuclearenvelope reassembly did not result in the recruitment of noncore, nuclearenvelope components to lagging chromosomes. These findings suggest that a dedicated chromosomeseparation checkpoint is unlikely to exist in human cells. Instead, chromosome segregation to the daughter cells and nuclearenvelope assembly are not closely coordinated events. This could explain why lagging chromosomes often form micronuclei with deficient nuclear envelopes, rather than being incorporated into the nucleus.
How microtubules might limit the access of noncore, nuclearenvelope components to lagging chromosomes is unknown. The noncore and core components of the nuclear envelope both include membranebound proteins that redistribute during cell division to an organelle called the endoplasmic reticulum. One possibility is that these core and noncore proteins localize to different parts of the endo plasmic reticulum. Perhaps sheetlike domains of the organelle that are too large to enter spin dle regions that have high micro tubule density might contain noncore proteins, whereas the smaller tubular structures of the endoplasmic reticulum that might be able to enter the spin dle regions could contain the core proteins. Alternatively, perhaps the localization of core and noncore nuclearenvelope proteins might be regulated by the micro tubuleassociated proteins that remove nuclearenvelope lipid membranes from chromosomes during an early stage of cell division 10 . 
I
t is estimated that 36.9 million people worldwide are infected with HIV (go.nature.com/2pugvhd). Drug treatment can prevent this infection from developing into AIDS and becoming lethal, by controlling the level of virus in the bloodstream. However, this therapy doesn't eradicate HIV, and is associ ated with toxicity and conditions such as meta bolic disorders 1 . As part of on going efforts to improve the treatment options available, clini caltrial results are now reported in two papers from the same research group -one in Nature by Mendoza et al. 2 (page 479) and the other by BarOn et al. 3 in Nature Medicine. The studies assess the effects of a treatment for HIV that uses two antibodies to target a viral protein.
The current standard treatment for HIV infection is longterm use of antiretroviral therapy (ART), a daily regime of drugs that block steps needed for viral replication. If ART treatment ceases, virus becomes detectable in the bloodstream within days, a phenomenon termed viral rebound that can lead to progres sion towards AIDS. ART does not provide a cure because the drugs do not kill infected cells in the viral reservoir 4 , which is established when virus inserts its genome into the genome of a host immune cell (Fig. 1) .
ART drugs can prevent viral production from the part of the reservoir termed the active viral reservoir, in which viral replication occurs. However, these drugs cannot target the viral reservoir that exists in a 'dormant' state, termed the latent viral reservoir. A latent viral reservoir can exist in certain tissues 5 ; here, virus production occurs at an extremely low level and might increase in the future. This 'hidden' reservoir can evade destruction by There has been interest in the potential use of HIVtargeting antibodies to control the viral level in the bloodstream. Such antibodies can bind to and block a protein on the viral sur face called Env, which is needed for HIV entry into host immune cells called CD4 + T cells. The discovery 6 of highly potent antibod ies, termed broadly neutralizing antibodies (bNAbs), boosted this idea. These antibod ies target regions of the Env molecule that are present in nearly all HIV strains. Individual bNAbs have already been tested [6] [7] [8] [9] for use as clinical treatments for HIV. They are safe and well tolerated 10, 11 , and, in contrast to the daily dosage necessary for ART, administration is needed only every few weeks to maintain constant bNAb levels in the bloodstream and potentially in tissues.
Previous clinical studies [7] [8] [9] testing the individ ual effects of two bNAbs 12, 13 -either 3BNC117 or VRC01 -found that the level of HIV in the bloodstream was initially suppressed for 6-10 weeks, but then viral rebound occurred, and the studies [7] [8] [9] reported the presence of antibodyresistant viral variants.
Mendoza et al. and BarOn et al. carried out phase Ib clinical trials (smallscale trials to test the safety of a treatment) to investigate whether combining two bNAbs (3BNC117 and 101074) that target distinct sites on Env might decrease the probability of virus resist ance occurring, and might control virus levels in HIVinfected people who did not receive ART during the trial period. Mendoza and colleagues assessed the effect of giving the two antibodies to 11 people who were temporarily stopping ART. BarOn and colleagues analysed the effect of these two bNAbs on seven people who hadn't yet received ART.
Both studies reported an impressive reduc tion in bloodstream HIV levels compared with levels at the start of the trial. Viral rebound took many weeks to occur, and when it did, there was little or no evidence that viruses were resistant to both bNAbs. This suggests that using two antibodies might offer an alternative treatment option to ART, pending further studies.
Mendoza and colleagues observed that resistance to 101074 developed more rapidly than that to 3BNC117. This could be explained if there was a more rapid natural decline in the blood levels of 3BNC117, which had a shorter halflife than 101074. It effectively resulted in periods of treatment with a single type of bNAb rather than with the intended two. If the antibody dosage could be adjusted so that the halflives of the two bNAbs were more closely matched, the development of treatment resistant viral variants might be avoided. However, triple antibody combinations might be necessary to tackle the emergence of antibody resistance.
Maintained viral suppression from antibody treatment was evident in Mendoza and col leagues' study. The authors found that when the bNAbs were introduced 2 days before ART was stopped, and further doses given 3 and 6 weeks later, virus in the bloodstream was suppressed to undetectable levels for a median time of 21 weeks before viral rebound. The rebound timeframe ranged from 5 to 30 weeks, and 9 of the 11 trial participants maintained viral suppression without rebound for more than 15 weeks.
One way to determine whether the charac teristics of viral infection change after bNAb therapy is to compare the diversity of the nucleotide sequences that encode the Env pro tein before and after treatment. Mendoza and colleagues found that the rebounding viruses after antibody treatment had low sequence diversity, whereas a high degree of diversity has been observed in viral rebound after ART treatment 14, 15 . It is possible that this differ ence arises because the antibodies restrict the growth of viruses from the tissue viral reser voir, in addition to targeting actively replicat ing viruses in the bloodsteam, leading to a low level of sequence diversity.
How effectively might antibodies control virus levels without pretreatment with ART? In BarOn and colleagues' study, the treatment suppressed virus levels in the bloodstream for an average of 86 days, about 60 days longer than previously observed 7 after treatment with just one HIVtargeting bNAb. This dual treatment approach in people who already had detectable levels of HIV in their bloodstream clearly limited the emergence of resistant viral variants, providing a notable advance on treat ment with a single type of antibody. However, suppression was complete only in people who had low levels of virus in their bloodstream at the beginning of the trial.
The results provide cause for optimism that a cocktail of antibodies might provide substan tial and durable viral control in the absence of ART. However, such enthusiasm must be tem pered with caution. BarOn and colleagues ini tially conducted laboratory tests to determine whether their study participants had a viral strain that would be sensitive to the bNAbs. In three individuals in whom the virus level rebounded most quickly, these antibodysensi tivity tests failed to detect viruses that had par tial or complete preexisting resistance to one or This interaction enables the virus to enter the cell, undergo DNA synthesis using the viral RNA template, and become inserted into the hostcell genome. Cells that are actively making virus using these inserted copies of viral DNA are called the active viral reservoir, and virus particles are released from such cells after viral replication. However, some cells that have viral DNA insertions might be in a 'dormant' state that does not actively produce virus and instead forms what is known as the latent viral reservoir; these cells might give rise to virus production in the future. b, BarOn et al. 3 report the results of a clinical trial that tested whether the introduction of two antibodies, 3BNC117 and 101074, which are a type of antibody known as a broadly neutralizing antibody (bNAb), can lower the blood levels of HIV in people who haven't received HIV treatment. The two antibodies bind to separate sites on Env, and prevent the virus from binding and infecting immune cells. c, The standard treatment for HIV infection is known as antiretroviral therapy (ART), and consists of a daily dose of drugs that block steps in viral replication. d, Mendoza et al. 2 report a clinical trial that tested whether 3BNC117 and 101074 can lower virus levels in the bloodstream of people who temporarily stop receiving ART. The results of both studies are encouraging, indicating that the use of two bNAbs can lower virus levels for a time.
t is reasonable to expect that to guide a mechanical structure through a complex, predetermined series of shape changes, electronic controls would be needed. In many cases, motors move the structure, sen sors detect position and electronic devices called microcontrollers execute algorithms to provide external control. Achieving com plex motion using only the structure's geom etry might seem unrealistic, but, if possible, it would have many advantages. In particular, it would simplify the manufacture of mechanical structures and enable them to be readily pro duced in various sizes. On page 512, Coulais et al. 1 report an approach for designing mater ials that follow a prescribed motion and that then reconfigure at specified points to enter another phase of motion. This movement is guided only by the material's geometry, which eliminates the need for external sensing and control.
Engineered str uc tures known as mechanical metamaterials are designed to behave in ways not common in nature [2] [3] [4] . They are usually made by combining building blocks (unit cells) into patterns, to produce a combined structure that can behave in ways not possible using a solid material. Advances in materials, manufacturing, computational capabilities and mechanicaldesign approaches are enabling designs that were not previously possible, such as the mechanical metamaterials described by Coulais and colleagues.
The authors used thin, flexible parts, strategically combined with thick, stiff parts, to achieve the desired structural motion. They refer to the movement of these parts as soft deformation, because it is caused by the bending of the flexible parts, rather than by mechanical hinges. This type of motion is not new, of course, because it can be seen exten sively in nature. Consider, for example, the movement of an elephant's trunk, your beat ing heart or a butterfly's flapping wings -in each case, motion results from the bending of flexible parts.
Designs in which a combination of flexible and stiff components enables a specified motion are often referred to as compliant mechanisms 5 . The use of these mechanisms in engineered materials offers several advan tages over conventional design methods, such as the ability to achieve complex motion from a single part rather than from an assembly of pieces connected by hinges. Coulais et al. used compliant mechanisms to realize surprisingly sophisticated multistep motions (Fig. 1) . One clever aspect of their approach is the use of parts that have different degrees of flexibility, so that, in response to an external force, some parts deform before others do.
Coulais and colleagues also used what they call selfcontact, whereby a stiff part is inten tionally brought into contact with another stiff part to prevent further motion between the two. This 'contactaided' mechanism 6, 7 is simi lar to a doorstop that prevents a door from colliding with a wall. In the authors' approach, bending of the most flexible part results in self contact, which ends the first step of a multistep pathway (Fig. 1a) . The most flexible part then becomes inactive, and the second step begins (Fig. 1b) . The nextmost flexible part becomes the main source of deformation, and this part bends until the next occurrence of selfcontact.
The authors produced unit cells from these flexible and stiff components, and combined the unit cells into patterns to achieve the desired motions. In one demonstration, they considered unit cells consisting of a crossshaped arrange ment of five equally sized squares, which were both bNAbs. This suggests that a moresensitive test than that used by the authors will be needed to assess whether people are likely to respond to a particular bNAb combination.
In the war against HIV, there has been some controversy regarding the use of bNAbs as a treatment approach. Antibodies have been thought of as providing defences equivalent to a naval blockade, stopping HIV from initially infecting or preventing the infection from spreading. But once this barrier is breached and infection takes hold, it is assumed that T cells are the front line of immune defence against infected cells, with anti bodies rel egated to bystander status. However, models of infection with a simian-human chimaeric virus called SHIV in primates suggest that antibodies might have an active role in tackling infected cells.
In these primate models, human antibod ies become widely distributed in tissues 16 , and could be acting in a manner equivalent to minesweepers, by limiting the spread of infection. Not only are such antibodies dis tributed efficiently to tissues far from the site of antibody administration, but they can also help to destroy infected cells, at least in the early stages of an infection, and to prevent the establishment of the viral reservoir 16, 17 . Once viral infection is established, the introduction of bNAbs that target Env can suppress the virus to undetectable levels in the bloodstream, as long as the antibodies persist there 18, 19 . The role of these antibodies in tissues is not fully understood. When the antibody levels decay, viral rebound occurs and immune defences are mediated mainly by T cells 20 . Given the results in primates, is there any evidence that bNAbs can tackle the viral res ervoir in human HIV infection? Mendoza and colleagues used an in vitro quantitative virus outgrowth test to assess the viralreservoir size. They found no significant differences in reservoir size before and after bNAb treat ment. However, longer and moreeffective bNAb treatment and larger study groups might be needed to establish definitively whether bNAbs affect the viral reservoir.
As strategies are sought to target the reservoir, it is encouraging to know that bNAbs might provide a useful weapon in the arsenal of viralcontrol tools. Moreover, if it turns out that a cocktail of bNAbs could act as a poten tial temporary replacement for ART, this type of 'drug holiday' might give people time to recover from ARTinduced toxicity. ■
